Compare H2O America (HTO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs BIO-TECHNE Corp — how do they compare? H2O America trades at $62.24 (market cap $2.56B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 4.4× H2O America's market cap, and H2O America pays the higher dividend (2.87%). Which is the better fit depends on your goals.
| HTO | TECH | |
|---|---|---|
Market Cap | $2.56B | $11.24B |
Sector | Technology | Health |
52-Week High | $65.43 | $72.29 |
52-Week Low | $44.44 | $43.31 |
Enterprise Value | $4.35B | $11.32B |
Dividend Yield | 2.87% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $62.66, up 1.42% with a bullish technical signal supported by moving averages. The company reported mixed earnings with Q2 2026 EPS beating expectations at $0.72 versus $0.699, but Q4 2025 missed. Fundamentals show strong gross margins at 56.91% and revenue growth to $829M projected for 2026. Recent news highlights institutional acquisitions and transformative Texas water utility expansion via the Quadvest deal.
Outlook remains positive with analyst consensus Buy rating (83%) and $69.50 price target offering ~11% upside. Key risks include execution challenges from acquisitions and EPS dilution from recent equity issuance. The dividend yield appears sustainable given cash flow trends, supporting income investors amid steady utility growth prospects.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
